Assistant Professor in Medicine-Hematology/Oncology, Northwestern University Medical School
Oncology
Dr. Mark Agulnik, MD
|
|
Give Review
Mark Agulnik is an expert in the field of Oncology. He researched medicine at University of Illinois College of Medicine at Chicago. University of Illinois College of Medicine at Chicago has a rank of 49 in research and a 85 in primary care He received awards:"Meaningful Use Stage 1 Certification" and "Super Doctor". Doctor Mark Agulnik, MD is a published doctor as well. He has 47 publications published. The latest was: Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Doctor Mark Agulnik, MD accepts Medicare.
Publications
- Targeted therapy and promising novel agents for the treatment of advanced soft tissue Sarcomas.
- A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
- Overview and Management of Dermatologic Events Associated With Targeted Therapies for Medullary Thyroid Cancer.
- Examination of national lymph node evaluation practices for adult extremity soft tissue Sarcoma.
- Effect of induction chemotherapy on swallow physiology and saliva production in patients with head and neck Cancer: A pilot study.
- Assessment of multimodality therapy use for extremity Sarcoma in the United States.
- Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma.
- Effect of Recombinant Human Deoxyribonuclease on Oropharyngeal Secretions in Patients With Head-and-Neck Cancers Treated With Radiochemotherapy.
- Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.
- Cixutumumab and temsirolimus for patients With bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
- Promising New Molecular Targeted Therapies in Head and Neck Cancer.
- New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
- New developments in mammalian target of rapamycin inhibitors for the treatment of Sarcoma.
- Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib.
- Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary Gland tumors treated with lapatinib.
- Increased risk of high-grade dermatologic toxicities With radiation plus epidermal growth factor receptor inhibitor therapy.
- The role of inhibitors of the epidermal growth factor in management of head and neck Cancer.
- Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pil...
- Promising newer molecular-targeted therapies in head and neck Cancer.
- Salivary Gland malignancies: the role for chemotherapy and molecular targeted agents.
- New therapeutic options in gastrointestinal stromal Tumors.
- Molecularly targeted therapies in adult soft tissue Sarcomas: present approach and future directions.
- Nasopharyngeal carcinoma: current management, future directions and dental implications.
- Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcino...
- Phase II trial of sorafenib in patients With recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
- Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients With recurrent or metastatic squamous cell carcinoma of the head and neck...
- Malignancies of the head and neck: the role for molecular targeted agents.
- The changing management of low-grade astrocytomas and oligodendroGliomas.
- Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel antiCancer agents.
- Recent advances in the treatment of oligodendroGliomas.
- Multidisciplinary Symposium on Head and Neck Cancer. 2 December 2005, Philadelphia, PA, USA.
- Integrative tumor board: colon Cancer with liver metastases: case presentation.
- Treatment of multiple keratoacanthomas With erlotinib.
- Targeted therapies in bone Sarcomas: current approach and future directions.
- Head and neck Cancer: changing epidemiology and public health implications.
- A phase II study of pazopanib in patients with recurrent or metastatic invasive Breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.
- Management of neuroendocrine Tumors of unknown origin.
- Occult primary.
- Oral complications of targeted Cancer therapies: a narrative literature review.
- Dermatologic infections in Cancer patients treated with epidermal growth factor receptor inhibitor therapy.
- Malignant lymphoma of mucosa-associated lymphoid tissue of the lacrimal Gland: case report and review of literature.
- Resource utilization for peritoneal catheter placement.
- Paclitaxel, carboplatin, and concomitant radiotherapy for resected patients with high risk head and neck Cancer.
- State-of-the-art management of nasopharyngeal carcinoma: current and future directions.
- An update on the systemic therapy of malignant salivary Gland cancers: role of chemotherapy and molecular targeted agents.
- Spotlight on lenvatinib in the treatment of thyroid Cancer: patient selection and perspectives.
Schools
McGill University Faculty of Medicine
Dalhousie University
University Ill Chicago
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Assurant Health
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Health and Life PPO
- Platinum PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- Harvard Pilgrim Health Care PPO
- Medicare Advantage PFFS
- HealthLink PPO
- Choice Care PPO
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- MVP Health Care
- Principal Life
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
University of Illinois College of Medicine at Chicago -
McGill University Faculty of Medicine
Hospital
-
Northwestern Memorial Hospital -
Lurie Children's Hospital of Chicago
Drug Facts
| NPI NUMBER | 1164448734 | |
| NPPES Provider LastName | AGULNIK | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 606115975 | |
| NPPES Provider State | IL | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 168.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 17.0 | |
| Percent Opioid Claims | 10.12 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1164448734 |
| Last Name Of The Provider | AGULNIK |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Nicklas R. Pfanzelter, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manjeet S. Chawla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Solomon S. Adler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marta Batus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth M. Hyjek, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin C. Conlon, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Boris Pasche, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Benjamin H. Yuen, MD |
|
|
Dr. Oana C. Danciu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Denise A. Levitan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah T. Lincoln, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ardaman P. Shergill, MD |
|
|
Dr. Caitlin O. Schein, MD |
|
|
Dr. Bryan S. Teruya, MD |